Skip to contentA
Apyx Medical Corp
A
APYXApyx Medical Corp Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$14.66M$14.66Mderived+16.3% vs Q4 2022 Net Income-$9.61M-$9.61MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Apyx Medical Corp · CIK 719135 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$8,929,000+8.3% Operating Incomederived-$5,776,000N/M Operating Cash Flowderived-$2,212,000N/M Free Cash Flowderived-$2,305,000N/M Margins · derivedGross margin60.9%−4.4 pt vs Q4 2022
Operating margin-39.4%+7.7 pt vs Q4 2022
Net margin-65.5%−17.6 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 21, 2024 · 81 d after period end